EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep
EMA’s human medicines committee (CHMP) has confirmed its initial recommendation to not renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) because recent data did not confirm its effectiveness; the benefits of Blenrep are therefore considered to no longer outweigh its risks.
News
Human
Medicines